Sana Biotechnology - SANA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.50
  • Forecasted Upside: 137.02 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.43
▼ -0.05 (-1.12%)

This chart shows the closing price for SANA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sana Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SANA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SANA

Analyst Price Target is $10.50
▲ +137.02% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Sana Biotechnology in the last 3 months. The average price target is $10.50, with a high forecast of $15.00 and a low forecast of $6.00. The average price target represents a 137.02% upside from the last price of $4.43.

This chart shows the closing price for SANA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Sana Biotechnology. This rating has held steady since May 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/8/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2022The Goldman Sachs GroupLower TargetNeutral$7.00 ➝ $6.00Low
5/17/2022Morgan StanleyLower TargetOverweight$15.00Medium
8/6/2021The Goldman Sachs GroupLower TargetNeutral$39.00 ➝ $34.00Low
3/1/2021JPMorgan Chase & Co.Initiated CoverageNeutral$35.00Low
3/1/2021Morgan StanleyInitiated CoverageOverweight$40.00Low
3/1/2021The Goldman Sachs GroupInitiated CoverageNeutral$40.00Low
3/1/2021Bank of AmericaInitiated CoverageBuy$45.00Low
(Data available from 12/8/2017 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/11/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/11/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/9/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/8/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/8/2022

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Sana Biotechnology logo
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $4.43
Low: $4.36
High: $4.53

50 Day Range

MA: $5.27
Low: $4.31
High: $6.46

52 Week Range

Now: $4.43
Low: $3.92
High: $19.69

Volume

365,517 shs

Average Volume

1,303,613 shs

Market Capitalization

$844.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Sana Biotechnology?

The following Wall Street research analysts have issued stock ratings on Sana Biotechnology in the last year: Morgan Stanley, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for SANA.

What is the current price target for Sana Biotechnology?

2 Wall Street analysts have set twelve-month price targets for Sana Biotechnology in the last year. Their average twelve-month price target is $10.50, suggesting a possible upside of 136.0%. Morgan Stanley has the highest price target set, predicting SANA will reach $15.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $6.00 for Sana Biotechnology in the next year.
View the latest price targets for SANA.

What is the current consensus analyst rating for Sana Biotechnology?

Sana Biotechnology currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SANA will outperform the market and that investors should add to their positions of Sana Biotechnology.
View the latest ratings for SANA.

What other companies compete with Sana Biotechnology?

Other companies that are similar to Sana Biotechnology include Immatics, Arcellx, Valneva, Aerie Pharmaceuticals and Agenus. Learn More about companies similar to Sana Biotechnology.

How do I contact Sana Biotechnology's investor relations team?

Sana Biotechnology's physical mailing address is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. The company's listed phone number is 206-701-7914 and its investor relations email address is [email protected] The official website for Sana Biotechnology is sana.com. Learn More about contacing Sana Biotechnology investor relations.